Skip to content

Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial

Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01179724
Enrollment
206
Registered
2010-08-11
Start date
2009-07-31
Completion date
2010-09-30
Last updated
2010-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delayed Bleeding

Brief summary

after endoscopic submucosal dissection(ESD) of early gastric cancer, conventional proton pump(PPI) inhibitors and H2 receptor antagonists have a controversial effect on preventing bleeding from artificial ulcers. the aim of this study was to investigate whether a stronger acid suppression (high dose PPI) more effectively prevents bleeding after ESD

Interventions

DRUGhigh dose proton pump inhibitor

IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month

DRUGH2RB

IV 50mg loading H2 receptor antagonist before 2hr to conduct ESD, and IV 13mg/h continuous infusion within 48hr, and then 300mg oral H2 receptor antagonist for one month

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* the patients who agreed informed consent * gastric adenoma or early gastric cancer which is eligible for conventional ESD indication

Exclusion criteria

* recent drug history of PPI, H2 rector antagonist, bismuth and antibiotics within 4 weeks * recent drug history of anticoagulant or antiplatelet agent within 7 days * s/p subtotal gastrectomy * recurred gastric adenoma or cancer * pregnant or breast feeding patients

Design outcomes

Primary

MeasureTime frame
bleeding incidence after ESDtime to occur delayed bleeding within one month after ESD

Secondary

MeasureTime frame
the size of healing ulcer after ESDfollow up endoscopy for the healing of iatrogenic ulcer after one month ESD

Countries

South Korea

Contacts

Primary ContactJae J Kim, professor
jjkim@skku.edu82-2-3410-3409

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026